Clinical economics review: medical management of inflammatory bowel disease

Fm, Ward; Bodger, Keith; Mj, Daly; Rv, Heatley

doi:10.1046/j.1365-2036.1999.00437.x

Cited by 66 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with the view that decreased economic productivity contributes significantly to the overall societal costs of Crohn's disease since the illness develops during patients peak employment years. 10 Our results are also consistent with the work of Blomqvist and Ekbom 13 who found that Swedish patients with IBD retired an average of 14 years prior to the mandatory age of retirement. This observation is consistent with our finding of high unemployment rates in all age groups in this study.…”

Section: Discussionsupporting

confidence: 95%

“…[1][2][3][4][5] As a result, Crohn's disease causes important disability and economic loss to patients and society. [6][7][8][9][10][11][12] Although inflammatory bowel disease (IBD) has been shown to result in a high cost to society, most analyses have likely underestimated the cost of IBD, since, for the most part, only direct costs have been considered. Indirect costs due to Crohn's disease are likely considerable.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease

Feagan¹,

Bala²,

Yan³

et al. 2005

Journal of Clinical Gastroenterology

110

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 95%

mentioning

confidence: 99%

Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease

Feagan¹,

Bala²,

Yan³

et al. 2005

Journal of Clinical Gastroenterology

110

View full text Add to dashboard Cite

show abstract

“…IBD is characterized by recurrent episodes and delayed healing, with its clinical manifestations of abdominal pain and diarrhea containing mucus, pus, and blood. The use of antibiotics and probiotics has been shown to be clinically effective for the treatment of IBD, in addition to traditional drug treatments such as amino salicylic acid drugs, corticosteroids, and immunosuppressive agents [26,27]. Traditional Chinese medicine has long been used in the treatment of IBD, because of its efficacy and lack of side effects [28][29][30].…”

Section: Original Papersmentioning

confidence: 99%

Astagalus Polysaccharide Attenuates Murine Colitis through Inhibiton of the NLRP3 Inflammasome

et al. 2016

View full text Add to dashboard Cite

polysaccharide is an important bioactive component of , an herb used in traditional Chinese medicine for treating inflammatory bowel disease. The NOD-like receptor protein 3 inflammasome plays an important role in the pathogenesis of inflammatory bowel disease. However, little is known about the role of NOD-like receptor protein 3 inflammasome in polysaccharide-treated mice with experimental colitis. For this study, we investigated the molecular mechanisms that underlie the treatment of inflammatory bowel disease by polysaccharide. We show that polysaccharide treatment reduces the disease activity index and histological injury scores compared to the colitis model group. polysaccharide also effectively inhibited the expression of NOD-like receptor protein 3, apoptotic speck protein containing a c-terminal caspase recruitment domain, caspase-1, interleukin-18, and interleukin-1, as shown by quantificational RT-PCR or the enzyme-linked immunosorbent assay. Furthermore, polysaccharide treatments produced significant dose-dependent improvements in dextran sulfate sodium-induced experimental colitis. Our data provide the reliable evidence that polysaccharide is able to exert a therapeutic effect in dextran sulfate sodium-induced colitis by inhibiting the activation of the NOD-like receptor protein 3 inflammasome, which acts to decrease the production of inflammatory factors such as interleukin-18 and interleukin-1.

show abstract

“…cure mediche, e in alcuni casi chirurgiche, e sono complessivamente un rilevante onere economico per il Sistema Sanitario Nazionale (SSN) e per la società [5].…”

Section: Farmeconomia E Percorsi Terapeutici 2003; 4 (4): 201-216unclassified

Mesalazina: profilo farmacologico, terapeutico e farmacoeconomico

Eandi

Ferrero

2003

View full text Add to dashboard Cite

NTRODUZIONELa malattia di Crohn e la colite ulcerosa, chiamate anche malattie infiammatorie croniche dell'intestino (IBD, da Inflammatory Bowel Disease), sono caratterizzate da disordini intestinali cronici di origine sconosciuta.Negli USA e in Europa l'incidenza della colite ulcerosa e del morbo di Crohn è stimata rispettivamente in circa 7 e 5 casi su 100.000 abitanti [1][2]. Questi valori, tuttavia, variano in relazione a fattori geografici ed ambientali, nonché in relazione a gruppi socioeconomici e alle origine etniche [3].È stato dimostrato un chiaro tratto genetico associato a queste malattie, tuttavia non sono stati chiariti i legami con numerosi fattori ambientali [4]. Entrambe le malattie possono presentarsi ad ogni età, ma più frequentemente nella terza decade di vita. Sebbene siano relativamente rare e raramente fatali, le IBD si presentano tipicamente nel periodo di vita economicamente produttiva dell'uomo, richiedono importanti e lunghe PROFILO ABSTRACTThe term inflammatory bowel diseases (IBD) refers to two distinct clinical entities: Crohn's disease and ulcerative cholitis, two chronic and non-specific disorders of unknown origin. Although quite uncommon and usually not life-threatening, IBDs have a strong economical impact, as they tend to affect patients in high productivity ages and require long and demanding therapies, medical and sometimes surgical. The pharmacological approaches to IBD treatment include aminosalicylates, corticosteroids and immunosuppressive agents. Aminosalicylic acids are the most widely used agents for maintaining remission and for the cure of mild-tomoderate forms of IBDs. This paper outlines the main pharmacological and clinical properties of one of these drugs, mesalamine (mesalazine). Mesalamine is the active moiety of sulfasalazine, an effective but not always tolerated agent. Mesalamine is available in several pharmaceutical forms, to be administered either by the oral or by the rectal route. As the therapeutic action of aminosalicylates is ascribed to their topical action on the inflamed intestine, while the adverse effects are believed to be caused by the systemically adsorbed (mainly in the first tract of the small bowel) fraction, slow-release formulations are usually preferred. From an economical point of view, mesalamine appears to have a moderate acquisition cost, widely offset by the savings induced on direct sanitary and, most importantly, indirect costs of IBDs. In particular, the availability of a generic drug with advanced colon-delivery technology provides the physician with the opportunity to treat patients with the best available technology at a reasonable price. Farmeconomia e percorsi terapeutici 2003; 4 (4): 201-216cure mediche, e in alcuni casi chirurgiche, e sono complessivamente un rilevante onere economico per il Sistema Sanitario Nazionale (SSN) e per la società [5].Gli approcci terapeutici alle IBD dipendono dall'estensione, dalle localizzazioni e dalla gravità della malattia, essi includono il trattamento con aminosalicilati, corticosteroid...

show abstract

Clinical economics review: medical management of inflammatory bowel disease

Cited by 66 publications

References 31 publications

Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease

Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease

Astagalus Polysaccharide Attenuates Murine Colitis through Inhibiton of the NLRP3 Inflammasome

Mesalazina: profilo farmacologico, terapeutico e farmacoeconomico

Contact Info

Product

Resources

About